BOLT
Bolt Biotherapeutics, Inc.Company with tickers: BOLT
Market Cap
$7.50M
Shares Outstanding
1,921,567
CIK
1641281
Website
Visit website
Investor Relations
Investor relations
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $26,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Revenue (ASC 606) | — | ||||
| Interest & Dividend Income | — | ||||
| Net Interest Income | — | ||||
| Noninterest Income | — | ||||
| Total Net Revenue | — | ||||
| Premiums Earned (Net) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $7,627,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $4,829,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-7,601,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-7,244,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-4.31 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-4.31 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |